1-(3-(methylsulfonyl)phenyl)ethanamine hydrochloride | 1191908-49-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(3-(methylsulfonyl)phenyl)ethanamine hydrochloride
• 英文别名: 1-(3-Methanesulfonylphenyl)ethan-1-aminehydrochloride；1-(3-methylsulfonylphenyl)ethanamine;hydrochloride
• CAS: 1191908-49-2
• 化学式: C₉H₁₃NO₂S*ClH
• 分子量: 235.735
• InChiKey: WPUWGOYXNWHBQX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.53
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  68.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(3-(methylsulfonyl)phenyl)ethanamine hydrochloride 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 caesium carbonate 、 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 1,4-二氧六环 、 乙醇 、 正庚烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 生成 (-)-8-(4-chlorophenyl)[1,6]naphthyridine-2-carboxylic acid [1-(3-methanesulfonylphenyl)ethyl]amide
  参考文献：
  名称：

  [EN] SUBSTITUTED 1,6-NAPHTHYRIDINES
  [FR] 1,6-NAPHTYRIDINES SUBSTITUÉES

  摘要：

  本发明涉及使用一般式（I）的化合物，其中R'是氢或较低的烷基；R1是卤素、较低的烷基、环烷基或氰基；或者是苯基，可选择地被一个到三个取代基取代，所述取代基选自较低的烷基、被卤素取代的较低烷基、较低的烷氧基、被卤素取代的较低烷氧基、卤素、氰基、羟基、C(O)-NH-较低烷基、CH2-C(O)-NH-较低烷基、CH2-NH-C(O)-较低烷基、CH2NH2、S(O)2CH3、S(O)2N(CH3)2，或者是由杂环烷基组成的基团；或者是吡唑-1、4或5-基，可选择地被较低烷基取代；或者是噻唑-5-基，可选择地被一个或两个较低烷基基团取代；或者是吡啶-2、3或4-基，可选择地被较低烷基、较低烷氧基、卤素或N(CH3)2取代；或者是3,6-二氢-2H-吡喃；或者是苯并[d][1,3]二噁嗪-5-基；或者是2,3-二氢苯并[b][1,4]二噁烷-6-基；R2是氢、较低烷基或被烷氧基取代的较低烷基；R3是氢、较低烷基、被卤素取代的较低烷基、被羟基取代的较低烷基、NH-S(O)2-CH3、-(CH2)m-O-较低烷基或-(CH2)n-S(O)2-CH3；或者是-(CR2)n-苯基，可选择地被-S(O)2CH3或较低烷氧基取代；或者是-(CH2)n-杂环烷基，可选择地被较低烷基和=O取代；或者是-(CH2)n-杂芳基，可选择地被一个或两个较低烷基基团取代；或者是-(CH2)n-环烷基，可选择地被氰基取代；或者R2和R3与它们连接的N原子一起形成一个杂环环，所述杂环环选自吗啉、哌啶、1,1-二氧代-硫代吗啉或哌嗪，可被较低烷基或C(O)O-较低烷基取代，或者可形成一个吡咯烷环，可选择地被羟基取代；R独立于n是氢或较低烷基；n为0、1、2、3；m为2；或者是药学上可接受的酸盐，或者是外消旋混合物，或者是其对应的对映体和/或光学异构体，用于治疗精神分裂症、强迫性人格障碍、抑郁症、躁郁症、焦虑症、正常衰老、癫痫、视网膜退化、创伤性脑损伤、脊髓损伤、创伤后应激障碍、恐慌障碍、帕金森病、痴呆症、阿尔茨海默病、轻度认知障碍、化疗诱导的认知功能障碍（“化疗脑”）、唐氏综合征、自闭症谱系障碍、听力丧失、耳鸣、脊髓小脑共济失调、肌萎缩侧索硬化、多发性硬化症、亨廷顿病、中风，以及由放射治疗、慢性应激、视神经病变或黄斑变性引起的干扰，或者由酒精、阿片类药物、甲基苯丙胺、芬太尼或可卡因等神经活性药物的滥用引起的干扰。

  公开号：

  WO2014079787A1
• 作为产物：
  描述：

  2-{1-[3-(methylsulfonyl)phenyl]ethyl}-1H-isoindole-1,3(2H)-dione 在 一水合肼 、 盐酸 作用下， 以 乙醇 、 1,4-二氧六环 为溶剂， 反应 2.0h， 生成 1-(3-(methylsulfonyl)phenyl)ethanamine hydrochloride
  参考文献：
  名称：

  EP2269989

  摘要：

  公开号：

文献信息

• [EN] NEUROGENESIS-STIMULATING ISOQUINOLINE DERIVATIVES<br/>[FR] DÉRIVÉS D'ISOQUINOLINE DE STIMULATION DE LA NEUROGENÈSE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2014177596A1

  公开（公告）日：2014-11-06

  The present invention relates to the use of compounds of general formula (I), wherein R1 is phenyl or pyridinyl, which are optionally substituted by halogen, cyano or lower alkyl substituted by halogen, or is dihydro-pyran-4-yl; R2 is hydrogen or lower alkyl; R3 is -(CHR)n-phenyl, optionally substituted by lower alkoxy or S(O)2-lower alkyl, or is heterocycloalkyl, optionally substituted by =O and lower alkyl, or is -(CH2)n-five or six membered heteroaryl, optionally sunbstituted by lower alkyl, or is hydrogen, lower alkyl, lower alkyl substituted by halogen, lower alkyl substituted by hydroxy, -NR-S(O)2-lower alkyl, -(CH2)n-cycloalkyl or -(CH2)n-S(O)2-lower alkyl; or R2 and R3 form together with the N-atom to which they are attached a heterocycloalkyl ring, selected from the group consisting of 1,1-dioxo-thiomorpholinyl, morpholinyl, or pyrrolidinyl, optionally substituted by hydroxyl; R is hydrogen or lower alkyl; n is 0, 1 or 2; or to a pharmaceutically acceptable acid addition salt, to a racemic mixture or to its corresponding enantiomer and/or optical isomers thereof, for the treatment of schizophrenia, obsessive-compulsive personality disorder, depression, bipolar disorders, anxiety disorders, normal aging, epilepsy, retinal degeneration, traumatic brain injury, spinal cord injury, post-traumatic stress disorder, panic disorder, Parkinson's disease, dementia, Alzheimer's disease, mild cognitive impairment, chemotherapy-induced cognitive dysfunction ("chemobrain"), Down syndrome, autism spectrum disorders, hearing loss, tinnitus, spinocerebellar ataxia, amyotrophic lateral sclerosis, multiple sclerosis, Huntington's disease, stroke, and disturbances due to radiation therapy, chronic stress, optic neuropathy or macular degeneration, or abuse of neuro-active drugs, such as alcohol, opiates, methamphetamine, phencyclidine or cocaine.

  本发明涉及使用一般式（I）的化合物，其中R1为苯基或吡啶基，可选择地被卤素、氰基或被卤素取代的较低烷基取代，或为二氢吡喃-4-基；R2为氢或较低烷基；R3为-(CHR)n-苯基，可选择地被较低烷氧基或S（O）2-较低烷基取代，或为杂环烷基，可选择地被=O和较低烷基取代，或为-(CH2)n-五元或六元杂环芳基，可选择地被较低烷基取代，或为氢、较低烷基、被卤素取代的较低烷基、被羟基取代的较低烷基、-NR-S（O）2-较低烷基、-(CH2)n-环烷基或-(CH2)n-S（O）2-较低烷基；或R2和R3与它们连接的N原子共同形成一个杂环烷基环，选自由1,1-二氧化硫代噻吩基、吗啉基或吡咯啉基，可选择地被羟基取代；R为氢或较低烷基；n为0、1或2；或是药学上可接受的酸盐，或为外消旋混合物或其对映体和/或光学异构体，用于治疗精神分裂症、强迫性人格障碍、抑郁症、躁郁症、焦虑障碍、正常衰老、癫痫、视网膜退化、创伤性脑损伤、脊髓损伤、创伤后应激障碍、惊恐障碍、帕金森病、痴呆症、阿尔茨海默病、轻度认知障碍、化疗诱导的认知功能障碍（“化疗脑”）、唐氏综合征、自闭症谱系障碍、听力丧失、耳鸣、脊髓小脑共济失调、肌萎缩性侧索硬化、多发性硬化症、亨廷顿病、中风，以及由放射治疗、慢性应激、视神经病变或黄斑变性、或滥用神经活性药物（如酒精、阿片类药物、甲基苯丙胺、芬太尼或可卡因）引起的干扰。
• SUBSTITUTED 1,6-NAPHTHYRIDINES
  申请人：Hoffmann-La Roche Inc.

  公开号：US20150252044A1

  公开（公告）日：2015-09-10

  The present invention relates to the use of compounds of general formula wherein R′ is hydrogen or lower alkyl; R 1 is halogen, lower alkyl, cycloalkyl or cyano; or is phenyl, optionally substituted by one to three substituents, selected from lower alkyl, lower alkyl substituted by halogen, lower alkoxy, lower alkoxy substituted by halogen, halogen, cyano, hydroxy, C(O)—NH-lower alkyl, CH 2 —C(O)—NH-lower alkyl, CH 2 —NH—C(O)-lower alkyl, CH 2 NH 2 , S(O) 2 CH 3 , S(O) 2 N(CH 3 ) 2 , or by heterocycloalkyl groups; or is pyrazol-1, 4 or 5-yl, optionally substituted by lower alkyl; or is thiazol-5-yl, optionally substituted by one or two lower alkyl groups; or is pyridine 2, 3 or 4-yl, optionally substituted by lower alkyl, lower alkoxy, halogen or N(CH 3 ) 2 ; or is 3,6-dihydro-2H-pyran; or is benzo[d][1,3]dioxol-5-yl; or is 2,3-dihydrobenzo[b][1,4]dioxin-6-yl; R 2 is hydrogen, lower alkyl or lower alkyl substituted by alkoxy; R 3 is hydrogen, lower alkyl, lower alkyl substituted by halogen, lower alkyl substituted by hydroxy, NH—S(O) 2 —CH 3 , —(CH 2 ) m —O-lower alkyl or —(CH 2 ) n —S(O) 2 —CH 3 ; or is —(CR 2 ) n -phenyl, optionally substituted by —S(O) 2 CH 3 or lower alkoxy; or is —(CH 2 ) n -heterocycloalkyl, optionally substituted by lower alkyl and ═O; or is —(CH 2 ) n -heteroaryl, optionally substituted by one or two lower alkyl groups; or is —(CH 2 ) n -cycloalkyl, optionally substituted by cyano; or R 2 and R 3 form together with the N atom to which they are attached a heterocyclic ring, selected from morpholine, piperidine, 1,1-dioxo-thiomorpholine or piperazine which may be substituted by lower alkyl or C(O)O-lower alkyl, or may form a pyrrolidine ring, optionally substituted by hydroxy; R is independently from n hydrogen or lower alkyl; n is 0, 1, 2, 3; m is 2; or to a pharmaceutically acceptable acid addition salt, to a racemic mixture or to its corresponding enantiomer and/or optical isomers thereof, for the treatment of schizophrenia, obsessive-compulsive personality disorder, depression, bipolar disorders, anxiety disorders, normal aging, epilepsy, retinal degeneration, traumatic brain injury, spinal cord injury, post-traumatic stress disorder, panic disorder, Parkinson's disease, dementia, Alzheimer's disease, mild cognitive impairment, chemotherapy-induced cognitive dysfunction (“chemobrain”), Down syndrome, autism spectrum disorders, hearing loss, tinnitus, spinocerebellar ataxia, amyotrophic lateral sclerosis, multiple sclerosis, Huntington's disease, stroke, and disturbances due to radiation therapy, chronic stress, optic neuropathy or macular degeneration, or abuse of neuro-active drugs selected from alcohol, opiates, methamphetamine, phencyclidine or cocaine.

  本发明涉及通式化合物的使用，其中R′为氢或低碳基；R1为卤素，低碳基，环烷基或氰基；或为苯基，可选地被一到三个取代基取代，所述取代基从低碳基，被卤素取代的低碳基，低碳氧基，被卤素取代的低碳氧基，卤素，氰基，羟基，C（O）-NH-低碳基，CH2-C（O）-NH-低碳基，CH2-NH-C（O）-低碳基，CH2NH2，S（O）2CH3，S（O）2N（CH3）2或杂环烷基组成；或为吡唑-1、4或5-基，可选地被低碳基取代；或为噻唑-5-基，可选地被一或两个低碳基取代；或为吡啶2、3或4-基，可选地被低碳基，低碳氧基，卤素或N（CH3）2取代；或为3,6-二氢-2H-吡喃基；或为苯并[d][1,3]二噁英-5-基；或为2,3-二氢苯并[b][1,4]二噁英-6-基；R2为氢，低碳基或被烷氧基取代的低碳基；R3为氢，低碳基，被卤素取代的低碳基，被羟基取代的低碳基，NH-S（O）2-CH3，（CH2）m-O-低碳基或（CH2）n-S（O）2-CH3；或为-（CR2）n-苯基，可选地被-S（O）2CH3或低碳氧基取代；或为-（CH2）n-杂环烷基，可选地被低碳基和═O取代；或为-（CH2）n-杂环芳基，可选地被一或两个低碳基取代；或为-（CH2）n-环烷基，可选地被氰基取代；或R2和R3与它们附着的N原子一起形成一个杂环环，所述杂环环从吗啉，哌啶，1,1-二氧-硫代吗啉或哌嗪中选择，所述杂环环可以被低碳基或C（O）O-低碳基取代，或可以形成一个吡咯烷环，可选地被羟基取代；R独立于n为氢或低碳基；n为0,1,2,3；m为2；或为其相应的对映异构体和/或光学异构体的药学上可接受的酸盐或外消旋体，用于治疗精神分裂症，强迫性人格障碍，抑郁症，双相情感障碍，焦虑症，正常衰老，癫痫，视网膜退化，创伤性脑损伤，脊髓损伤，创伤后应激障碍，恐慌症，帕金森病，痴呆，阿尔茨海默病，轻度认知障碍，化疗引起的认知功能障碍（“化疗脑”），唐氏综合症，自闭症谱系障碍，听力损失，耳鸣，脊髓小脑性共济失调，肌萎缩侧索硬化症，多发性硬化症，亨廷顿病，中风以及由放射治疗，慢性压力，视神经病变或黄斑变性，或滥用酒精，阿片类药物，甲基苯丙胺，苯环利定或可卡因等神经活性药物引起的干扰。
• ISOQUINOLINE DERIVATIVES
  申请人：Hoffmann-La Roche Inc.

  公开号：US20160046583A1

  公开（公告）日：2016-02-18

  The present invention relates to the use of compounds of general formula wherein R 1 is phenyl or pyridinyl, which are optionally substituted by halogen, cyano or lower alkyl substituted by halogen, or is dihydro-pyran-4-yl; R 2 is hydrogen or lower alkyl; R 3 is —(CHR) n -phenyl, optionally substituted by lower alkoxy or S(O) 2 -lower alkyl, or is heterocycloalkyl, optionally substituted by ═O and lower alkyl, or is —(CH 2 ) n -five or six membered heteroaryl, optionally substituted by lower alkyl, or is hydrogen, lower alkyl, lower alkyl substituted by halogen, lower alkyl substituted by hydroxy, —NR—S(O) 2 -lower alkyl, —(CH 2 ) n -cycloalkyl or —(CH 2 ) n —S(O) 2 -lower alkyl; or R 2 and R 3 form together with the N-atom to which they are attached a heterocycloalkyl ring, selected from the group consisting of 1,1-dioxo-thiomorpholinyl, morpholinyl, or pyrrolidinyl, optionally substituted by hydroxyl; R is hydrogen or lower alkyl; n is 0, 1 or 2; or to a pharmaceutically acceptable acid addition salt, to a racemic mixture or to its corresponding enantiomer and/or optical isomers thereof, for the treatment of schizophrenia, obsessive-compulsive personality disorder, depression, bipolar disorders, anxiety disorders, normal aging, epilepsy, retinal degeneration, traumatic brain injury, spinal cord injury, post-traumatic stress disorder, panic disorder, Parkinson's disease, dementia, Alzheimer's disease, mild cognitive impairment, chemotherapy-induced cognitive dysfunction (“chemobrain”), Down syndrome, autism spectrum disorders, hearing loss, tinnitus, spinocerebellar ataxia, amyotrophic lateral sclerosis, multiple sclerosis, Huntington's disease, stroke, and disturbances due to radiation therapy, chronic stress, optic neuropathy or macular degeneration, or abuse of neuro-active drugs, such as alcohol, opiates, methamphetamine, phencyclidine or cocaine.

  本发明涉及使用通式化合物，其中R1是苯基或吡啶基，可以通过卤素、氰基或受卤素取代的较低烷基取代，或者是二氢吡喃-4-基；R2是氢或较低烷基；R3是-（CHR）n-苯基，可以通过较低烷氧基或S（O）2-较低烷基取代，或者是杂环脂肪基，可以通过═O和较低烷基取代，或者是-（CH2）n-五或六元杂环芳基，可以通过较低烷基取代，或者是氢、较低烷基、受卤素取代的较低烷基、羟基取代的较低烷基、-NR-S（O）2-较低烷基、-（CH2）n-环烷基或-（CH2）n-S（O）2-较低烷基；或R2和R3与它们连接的N原子一起形成一个杂环脂肪基环，选择自由基团1,1-二氧代硫代吗啉基、吗啉基或吡咯烷基，可以通过羟基取代；R是氢或较低烷基；n是0、1或2；或其药学上可接受的酸盐、外消旋混合物或其对应的对映异构体，用于治疗精神分裂症、强迫性人格障碍、抑郁症、双相障碍、焦虑障碍、正常老化、癫痫、视网膜退化、创伤性脑损伤、脊髓损伤、创伤后应激障碍、惊恐障碍、帕金森病、痴呆症、阿尔茨海默病、轻度认知障碍、化疗诱导的认知功能障碍（“化疗脑”）、唐氏综合症、自闭症谱系障碍、听力损失、耳鸣、脊髓小脑性共济失调、肌萎缩性侧索硬化症、多发性硬化症、亨廷顿病、中风以及由放射治疗、慢性应激、视神经病变或黄斑变性、神经活性药物滥用，如酒精、鸦片类、甲基苯丙胺、苯环利定或可卡因引起的干扰。
• IMINOPYRIDINE DERIVATIVE AND USE THEREOF
  申请人：Yoshida Masato

  公开号：US20110039892A1

  公开（公告）日：2011-02-17

  The present invention aims to provide a compound having a superior selective α 1D adrenergic receptor antagonistic action and useful as an agent for the prophylaxis or treatment of a lower urinary tract disease and the like. The present invention provides a compound represented by the formula (I) wherein each symbol is as defined in the specification, or a salt thereof.

  本发明旨在提供一种化合物，具有优异的选择性α1D肾上腺素能受体拮抗作用，并且可用作预防或治疗下尿路疾病等药物。本发明提供一种由式(I)表示的化合物或其盐，其中每个符号如规范中所定义。
• NEUROGENESIS-STIMULATING ISOQUINOLINE DERIVATIVES
  申请人：F.Hoffmann-La Roche AG

  公开号：EP2991635A1

  公开（公告）日：2016-03-09